🎯

PACE-B

SBRT

Definitive - PACE-B Trial - 36.25 Gy/5 fx

Dose Oracle
PREFERRED36.25 Gy / 5 fx(7.25 Gy/fx)BED₁₀ = 62.5 Gy• PACE-B protocol dose

Indication

Localized prostate cancer, low to intermediate risk, definitive ultra-hypofractionated SBRT

Eligibility Criteria

  • Low-risk: T1-T2a, Gleason ≤6, PSA <10
  • Intermediate-risk: T2b-c, Gleason 7, or PSA 10-20
  • No nodal or metastatic disease
  • Prostate volume <100cc preferred
  • IPSS ≤15
  • No prior pelvic RT

Staging

cT1-T2c N0 M0

Tags

SBRTProstate5 fractionDefinitiveLow-riskIntermediate-riskPACE